Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was pounding the table to BUYBUYBUY when GERN was at $2.00 I said it many times on here in the last 4 years, also, that GERN was a gift at that price...GERN is still a gift at $4.00! Time is running out for YOU KNOW WHO to cover! GO GERN! LONG & STRONG!
ImetelChat
discussions on imetelstat and telomerase
(08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, incl imetelstat
• Quote
Postby Fishermangents » Sat Apr 14, 2018 8:46 pm
(08-02-2018) - Janssen BioTech applies for global patent for COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS, including Imetelstat.
The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
Dano . YB.
Huge UP day tomorrow!!! As of April 13th, there was short interest of 34,979,045 shares, a decrease of 20.7% from the March 30th total of 44,086,309 shares. Currently, 21.9% of the company's stock are short sold. Based on an average daily trading volume, of 7,746,395 shares, the days-to-cover ratio is presently 4.5 days. Couple this with the fact that end of trial was moved one week closer to COINCIDE with J&J annual meeting on April 26. Big announcement coming!!! Shorts will try to cover tomorrow
http://www.wsj.com/mdc/public/page/2_3062-nasdaqshort-highlites.html
10 New Blockbusters by 2019, J&J's Janssen Predicts They include: The human anti-CD38 antibody daratumumab for multiple myeloma, developed under an up-to-$1 billion licensing deal with Genmab inked in 2012; the modified oligonucleotide imetelstat for myelofibrosis, co-developed with Geron under an up-to-$935 million collaboration; the FGFRi kinase inhibitor JNJ-493 for urothelial cancer; and the androgen receptor signaling inhibitor JNJ-927 (ARN-509) for pre-metastatic prostate cancer, inherited when J&J acquired Aragon Pharmaceuticals for up to $1 billion in 2013.
https://www.genengnews.com/gen-news-highlights/10-new-blockbusters-by-2019-jjs-janssen-predicts/81251292?q=Imetelstat
4/23/2018 Geron Corporation: The Clock Is Ticking
At present, J&J's pharma subsidiary has 170 ongoing clinical trials, according to clinicaltrials.gov -- only two of which pertain to imetelstat. The point is that J&J decided to earmark imetelstat as a top prospect -- even though it literally has dozens upon dozens of other promising drug candidates. That's a sure sign of confidence, in my book
https://finance.yahoo.com/news/geron-corporation-clock-ticking-140000847.html
Johnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug
https://seekingalpha.com/amp/article/4164027-johnson-and-johnson-reaffirms-gerons-imetelstat-lead-oncology-pipeline-drug
TT you Super LIAR ..... absolutely nothing to substantiate these claims of a RS has been posted. and this is not secret .. your time is gone ......now you .. time loser.. CONFIRMED..
p.s. your opinion fairly valued - under 0 ...
https://i.imgur.com/1Dgj7Xk.pngThis is Adam Feuerstein a writer on some website called STAT. after a insane run up in the stock price this year the shorts were getting very desperate. this is why on march 27th 2018 at 7am Adam feurestein was asked by shorties to write a #$%$ article about Geron. he called the data flimsy and basically called the CEO a liar. On that same day at 4pm the CEO of Geron was to present at the needham healthcare conference. It was this that the shorts were afraid of. The price went down the whole day until the conference. At the needham healthcare conference the CEO of Geron presented good news. Following the conference, the price climbed back up considerably. as a final desperate attempt just before when after-hours trading ends, a law firm by the name Pomerantz quotes Fartstain#$%$ piece and announces an investigation on behalf of shareholders against GERON. The law firm gets the date of Adam Fartstain's article wrong. Several other law firms follow suite the following trading days. They too, get the date wrong. File your SEC complaint about this incident. Price manipulation is a crime and they deserve jail time.
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at Imedex Great Debates 2018.
http://www.oncologytube.com/video/imetelstat-telomerase-inhibitor-myelofibrosis-intravenous-drug-given-every-3-4-weeks/10003699
If GOD with us , who is against us ??? Adam F? ....... very sad about him... going around , come in around.... he will get , what he deserve ..........
18 YEARS TRADING ex·pe·ri·ence .... RULE !#1 IF <<The Street>> said - SELL , YOU HAVE TO BUY , BUY AND STRONG BUY - ASAP !!!
Multiple upcoming catalysts could see GERN shares soar into the teen or higher. For JNJ, Imetelstat may soon join the ranks of their mega-blockbuster drugs with worldwide sales of $4 billion per year and above, yielding sizable gains for shareholders.
https://seekingalpha.com/article/4164027-johnson-and-johnson-reaffirms-gerons-imetelstat-lead-oncology-pipeline-drug
11/2017 GERN is Fast track designation is designed to aid in the development and expedite the review of drugs which show promise in treating a serious or life-threatening disease and address an unmet medical need.
https://en.wikipedia.org/wiki/Fast_track_(FDA)
There are now at 3 main drug companies that need Geron's cancer drug desperately over several indications. J&J (Janssen), Incyte, Celgene, and now Merck plus Abbvie are watching closely with possible combo drugs. Now that the company has confirmed imetelstat’s superior results, (that in effect make Incyte’s and Celgene’s drug obsolete) things are heating up with Geron’s share price, recently more than doubling, and the other competitors continue freefalling by 65-75%. Additional companies that need Imetelstat in their stable are, but not limited to Merck and Abbvie. Ask President Jimmy Carter how he feels about the Keytruda-Imetelstat combo research. Also ask about the Imetelstat combo research with ABT-199. As more good news leaks out in the approaching events timeline, this stock is likely to continue on it’s parabolic trajectory.
Johnson and Johnson CFO just said 1.50 seconds into Bloomberg interview, "We plan to file 8 additional medictioeach having OVER $1 BILLION IN SALES BUY 2021." FOLKS THIS IS GERN!!!
Very Nice GERN article , just out :
•Insiders have tipped their hands as to what the future holds for GERN.
•Imetelstat has a history of positive FDA decisions.
•There is enough information out there to reach a sound and logical decision to invest in GERN.
https://seekingalpha.com/article/4163482-logical-argument-geron?auth_param=1f1f9c:1ddc4sg:6f8c5052bb3946cc2b6f2e8e822dafde&dr=1
Johnson & Johnson's first quarter earnings for 2018 are due on Tuesday, April 17th 2018. Along with the usual financial statements, the manufacturing giant is expected to present new clinical data from its pipeline. As Johnson & Johnson has consistently named imetelstat as one of its leading blockbuster-potential drugs and since Geron's management themselves have hinted that promising clinical results are forthcoming, it would be extremely odd for Janssen Biotech to not address the issue soon. Not doing so would be a major red flag.
https://seekingalpha.com/article/4163460-geron-faces-make-break-catalyst-week?auth_param=1f1f9c:1ddbuuc:7717436dfaec7e5dbcfdeeb1b79ea219&dr=1
4/17/2018
•Geron's lead drug candidate imetelstat, developed in collaboration with Johnson & Johnson subsidiary Janssen Biotech, is facing a key catalyst ahead.
•If Janssen elects to continue backing the development of imetelstat into Phase 3 trials, Geron will receive a guaranteed payout; if not, the small biotech could fold.
•Johnson & Johnson is expected to signal its intentions when it announces earnings on April 17.
•Promising comments from Geron's management suggest that Johnson & Johnson's decision will be a positive one for the company.
•Geron represents a serious case of high risk, high reward trading.
https://seekingalpha.com/article/4163460-geron-faces-make-break-catalyst-week?auth_param=1f1f9c:1ddbuuc:7717436dfaec7e5dbcfdeeb1b79ea219&dr=1
Adam Feuerstein // Stock Market’s Sméagol
https://thestockcop.wordpress.com/2016/09/02/adam-feuerstein-stock-markets-smeagol/
Drop the mic. Filing 2018-2021. Less than 6 months from now the decision comes through with a filing even possible. Who's going to sell 44 million shares to the shorts? Who's going to sell 10 million? Not below $10, $20, or $30. Game over shorts, thanks for playing, thank you, come again. You didn't get a single share from me. And soon the SEC will come knocking at your door. Was it worth it?
Influenza A
Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
Selective Highlights as of April 17, 2018
NME PLANNED FILINGS 2018-2021*
TREMFYA® (guselkumab)
Psoriasis
ERLEADA™ (apalutamide) (EU)
Non-metastatic prostate cancer
Imetelstat
Myelofibrosis
http://www.investor.jnj.com/_document/johnson-johnson-pipeline-q1-2018?id=00000162-d33e-d077-af7a-fbff592e0000
http://www.investor.jnj.com/pharmaceutical-pipeline
Proof positive that Imetelstat is held in high regard by JNJ !!! Under Debi’s leadership the oncology team has executed several important transactions including the recent BCMA CAR-T/Legend deal, niraparib/TESARO, Imetelstat/Geron, and two deals with MacroGenics. With her guidance, the oncology team manages several significant alliances including the Ibrutinib alliance with Pharmacyclics/Abbie and Daratumumab with Genmab.
https://www.jnjinnovation.com/debi-watson
This guy is a Tool,,,,check Jim Cranmer Clown out.
Cramer said ,, don't buy NOK ,, back to Summer 2012 , I got $1.74c 20K shares , sold next Fall 2013 for $8.60c. Don't listen ,, Street clowns,,
February 8 2018 . But look like nobody pay attention..
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018026646
Additional late-stage blockbuster products1 projected to file for regulatory approvals between 2017 and 2021, include:
•apalutamide (ARN-509) for pre-metastatic prostate cancer;
•esketamine for treatment-resistant depression;
•talacotuzumab (CSL362) for acute myeloid leukemia;
•erdafitinib (FGFR Inhibitor) for solid tumors;
•niraparib for prostate cancer;
•imetelstat for myelofibrosis;
•pimodivir (JNJ-3872) for influenza A;
•lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection; and,
•JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for major depressive disorder.
https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-strong-pipeline-of-transformational-medicines-at-its-pharmaceutical-business-review-meeting
selling daily . This shorts dump every morning , today 9.30 they sold 395K shares , they fight for each dime to cover . The time almost gone for shorts ... scare tactic..
PCYC only had 1 deal with JNJ and got bought out for $261.20 a share.
GERN has 2 deals with JNJ plus GERN has deals with BTX/AST plus GERN has a deal with Sienna that GERN is the largest share holder in Sienna plus GERN has over 300 patents and $110Mil. in cash.
NEWS out April 09, 2018 07:00 AM Eastern Daylight Time .
Acerus Announces Launch of URIVARX® in Canada
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced the launch of URIVARX® in Canada less than 3 months after securing the exclusive Canadian rights to the product from Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus”) earlier in the year.
Acerus had previously planned for the Canadian launch of URIVARX® in the second half of 2018, but the Company has arranged for the product to be available in Canada via the Innovus supply chain. This has helped Acerus, through its Innovus partner, to initiate direct to consumer campaigns and generate meaningful revenues in the first quarter. The Company intends to build on this solid start while its OTX platform and infrastructure are being implemented. Acerus expects its multi-level commercial platform to be fully implemented in the coming months, which will also enable its expanded commercial team to proactively detail URIVARX® to physicians.
“We are extremely pleased with the URIVARX® revenues achieved thus far in 2018. Thanks to the support of our partner Innovus, we have been successful in rapidly implementing marketing programs and securing Canadian sales in the first quarter. We expect URIVARX® sales to accelerate later this year after our OTX platform is fully operational,” said Tricia Symmes, Chief Operating Officer of Acerus.
https://www.businesswire.com/news/home/20180409005358/en/Acerus-Announces-Launch-URIVARX%C2%AE-Canada
TT.....going around , come in around ....I'm convinced you belong to the group of manipulators Damaj and his management team have identified during their investigations.... your time is gone....
YES , YOU ARE.....................
May 9-15 ..........
Successful Investing takes time, discipline and patience. No matter how great the talent or effort, some things just take time: You can’t produce a baby in one month by getting nine women pregnant. - The Oracle of Omaha (Warren Buffett)
Your opinion _ is a complete joke
told u so
Your opinion _ is a complete joke
told u so ........ we saw Total Revenue - ( ?12?/?31?/?2014 - $1,03 Mil. ?12?/?31?/?2015- 736K. ?12?/?31?/?2016 - $4,86 Mil.
2017 - 8.8Mil .)
WILL SEE - 22m 2018 45m 2019 nasdaq 90m 2020....
I've never heard this level of enthusiasm and confidence from Bassam since 2016. He is generally upbeat, but today, he's on fire. He reiterated no reverse split. Profitability this year. Multiple products lined up to become "core products" meaning $1M in sales per year. He just sent a strong warning to Shorts to cover their positions! Bam!!! YB.
Urivax alone expected to generate $6m in revenues for 2018. That's 67% of 2017 gross revs of $8.8m from one single product in 2018!
Net loss totaled $6.5 million, or $0.04 per common share, for the year ended December 31, 2017 compared to a net loss of $13.7 million, or $0.15 per common share ....... what are you talking ? poor 2017...? 2017 EXCELENT ... Specially 1q 2018
Very nice, very nice ..... 2017 , But you unhappy so, its your problem...nobody care about past ... Today 2018 , and 2017 REVENUE 100% UP FROM 2016 ...